Jasper Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	17.08	16.57	11.41	4.8	1.09
Research & Development	51.79	34.63	25.42	15.88	3.62
Operating Expenses	68.86	51.2	36.83	20.68	4.71
Operating Income	-68.86	-51.2	-36.83	-20.68	-4.71
Interest Expense / Income	0	0	0	0	0.53
Other Expense / Income	-4.4	-13.51	-6.2	10.99	-0.26
Pretax Income	-64.47	-37.69	-30.64	-31.67	-4.99
Net Income	-64.47	-37.69	-30.64	-31.67	-4.99
Shares Outstanding (Basic)	10	4	1	1	0
Shares Outstanding (Diluted)	10	4	1	1	0
Shares Change	186.15%	220.19%	85.99%	35.80%	-
EPS (Basic)	-6.18	-10.33	-26.90	-51.70	-11.10
EPS (Diluted)	-6.18	-10.33	-26.90	-51.70	-11.10
Free Cash Flow	-52.33	-46.43	-36.11	-18.27	-1.97
Free Cash Flow Per Share	-5.01	-12.73	-31.69	-29.82	-4.37
EBITDA	-62.94	-36.38	-30.07	-31.65	-4.45
Depreciation & Amortization	1.53	1.31	0.57	0.02	0
EBIT	-64.47	-37.69	-30.64	-31.67	-4.45

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).